How Much Does Remicade Infusion Cost?

Published on December 7, 2025 | Prices Last Reviewed for Freshness: January 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Remicade, the brand name for infliximab, is an intravenous biologic therapy for conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis and several other inflammatory disorders, and it is usually given in a hospital or infusion center over two to three hours.

The prices involved are often much higher than patients and families expect. For people in the United States, this article focuses on what Remicade infusion cost looks like on real-world bills so you can plan alongside advice from your own clinicians; it is not medical advice or a recommendation for or against any treatment.

Each infusion is weight based, so a heavier patient needs more vials than a lighter one, and the standard schedule starts with doses at weeks 0, 2 and 6 then moves to maintenance visits about every eight weeks.

That pattern means a typical person may sit in an infusion chair six to eight times a year, and every visit brings a separate bill that includes the drug, the professional service and facility fees, following dosing guidance similar to that on Remicade’s HCP dosing pages and insurer medical policies such as those from Blue Cross Blue Shield of Florida. For many households the ongoing cost of this therapy becomes one of the largest recurring medical expenses in the family budget.

Article Highlights

• Typical uninsured Remicade infusion charges are around $4,000–$7,000 in clinics and can reach $12,000+ in hospital outpatient departments in the United States.
• A full year of infliximab therapy often totals $30,000–$100,000 in billed charges before insurance, and dose escalations can push totals higher.
• Independent infusion centers and home programs can reduce allowed amounts by roughly 30 to 50 percent compared with hospitals, which directly lowers coinsurance for many patients.
• Biosimilars such as Inflectra, Avsola and Renflexis are typically priced 15 to 40 percent below Remicade at the average sales price level, although facility markups and benefit design still shape the final bill.
• Manufacturer savings programs and foundation grants can cut drug copays to as little as $5 per visit for eligible patients, while uninsured patients may negotiate cash package rates and discounted self pay bundles.
• Reviewing hidden items such as labs at $100–$250 and premedications at $25–$100 helps avoid surprise bills and gives a more realistic view of total Remicade therapy expense.

How Much Does Remicade Infusion Cost?

For a person paying the full bill without financial help, a single Remicade infusion often falls in the $4,000–$7,000 range in United States outpatient clinics, and in some hospital outpatient departments total charges can reach $12,000+ for one visit in the 2024-2025 period. These totals usually combine the infliximab drug charge with the infusion service and pharmacy preparation, and published estimates from pharmacy benefit tools such as SingleCare’s Remicade cost analysis and infusion centers like My Local Infusion’s Remicade breakdown cluster in the same bands even though individual line items vary widely.

When the induction phase and maintenance visits are added together, a year of treatment can exceed $30,000–$100,000, especially for patients who need higher doses or more frequent infusions because of severe or refractory disease.

SingleCare estimates that an uninsured dose commonly falls between $4,000–$7,000, and Local Infusion notes that Remicade can total $50,000–$150,000 across a year of therapy depending on body weight and frequency, which matches the experience shared by many infusion centers and hospital billing files. Put another way, a year at the upper end of that range can rival what many United States households earn before tax, so understanding these figures in advance is important before committing to long term infliximab therapy.

Charges also differ by geography and health system. Hospital price transparency documents from systems such as Carson Tahoe Health and Lawrence General Hospital list self pay charges above $6,000 for a single 100 milligram Remicade vial, whereas an analysis from EVERSANA on biosimilar pricing in Europe found that manufacturer prices for that same vial in several large European markets generally sat around €430–€500, which helps keep patient out of pocket amounts lower in countries with national insurance.

What Affects the Cost?

Remicade dosing is set in milligrams per kilogram, commonly 5 milligrams per kilogram for Crohn’s disease and ulcerative colitis, and the drug is supplied in 100 milligram vials that cannot be shared between patients once a vial is opened. A 70 kilogram adult on a 5 milligram per kilogram regimen needs 350 milligrams, which means four vials, and current pricing data on infliximab from tools such as Drugs.com’s Remicade price guide place 100 milligram vials near $1,100–$1,200 at retail and around $800 in some self pay gastroenterology clinics such as Woodholme Gastroenterology’s fee schedule, so vial count is one of the largest drivers of infusion cost in any therapy plan.

Standard induction covers three visits over six weeks, then maintenance visits repeat every six to eight weeks as long as the medicine is effective, but some patients move to higher doses or shorter intervals if disease activity rises.

When the interval drops from eight weeks to six, annual drug volume climbs by roughly one third, and that shift alone can push a person from the lower end of the yearly price band into the $80,000–$100,000 bracket before any insurance adjustments or discounts, following patterns similar to those described on Remicade professional dosing pages and in patient facing explanations from Medical News Today. Because Remicade is often used as a long term maintenance therapy, these dose changes over time are a major reason total yearly Remicade infusion cost can rise faster than patients expect.

You might also like our articles on the cost of Vyepti infusions, Reclast infusions, or iron infusions.

On top of the medication itself, providers bill for nursing time, IV start, premedication such as acetaminophen and antihistamines, chair time and post infusion observation, and they may add separate laboratory panels or physician visits on the same date.

United Digestive’s published infusion FAQ (United Digestive infusion FAQ) and community infusion centers like My Local Infusion both note that when you add the drug itself, the infusion chair, nursing time, IV supplies, premedication and post infusion monitoring, a visit that lasts only a few hours can easily generate a bill that reaches several thousand dollars.

Cost with Insurance

Most Remicade use in the United States runs through medical benefits instead of the pharmacy card, so the drug is billed under commercial medical plans or Medicare Part B. Under Part B, the program typically pays the average sales price plus a small percentage for infliximab, then the patient is responsible for 20 percent coinsurance after meeting the Part B deductible, which means a person facing a $6,000 allowed amount could owe about $1,200 for that infusion unless they carry a Medigap or Medicare Advantage plan that reduces the share, according to explanations from SingleCare and the Centers for Medicare & Medicaid Services Part B drug pricing files.

The allowed amount is usually lower than the hospital’s starting price because insurers negotiate discounts, but coinsurance is calculated from that allowed figure, not from the initial chargemaster number.

For people covered by employer or marketplace policies, out of pocket costs depend on the annual deductible, coinsurance rate and whether the infusion center is in network. A high deductible plan with a $3,000 deductible and 20 percent coinsurance might leave a patient paying nearly the full allowed amount for the first visit of the year, then only several hundred dollars for later infusions once the deductible and out of pocket maximum are met, following the general structure of high deductible health plans described on HealthCare.gov.

Most Affordable Care Act compliant plans cap total in network out of pocket spending each year, so once that ceiling is reached, additional Remicade infusions in the same year are often covered at or close to 100 percent.

Manufacturer assistance can change these numbers for commercially insured patients. The J&J withMe savings program for Remicade states that eligible people may pay as little as $5 per infusion for the drug portion of the bill up to an annual maximum, although the program does not cover the facility fee or charges for other services, and nonprofit foundations sometimes step in to help with the remaining balances when people meet income and diagnosis criteria.

Details appear on the J&J withMe infliximab affordability page. Because of United States anti kickback rules, these manufacturer copay cards generally cannot be used by people whose primary coverage is Medicare or Medicaid, who instead rely on independent foundations or secondary insurance.

Cost Without Insurance

Uninsured people or those whose plans deny coverage for Remicade face some of the highest raw prices in outpatient care. My Local Infusion reports that Remicade charges typically fall between $3,000–$12,000 per treatment and can reach $50,000–$150,000 over a full year of care, and this matches list prices quoted by United States hospitals and price transparency tools that show large markups on each 100 milligram vial, such as those published by Carson Tahoe Health.

Consumer guides such as SingleCare’s overview of Remicade without insurance likewise place a typical self pay dose in the $4,000–$7,000 band once drug and administration fees are combined.

In a self pay gastroenterology clinic in Maryland, the posted fee schedule lists Remicade or Avsola at $800 per vial and $400 for the infusion administration, so a 70 kilogram patient on a 5 milligram per kilogram dose would need four vials, or $3,200 in drug charges, plus the $400 administration fee, a new patient visit near $250 and routine lab work around $150, creating a first infusion bill close to $4,000 before any prompt pay discount, as illustrated by Woodholme Gastroenterology and United Digestive’s infusion FAQ.

Clinics sometimes offer package pricing or early payment discounts to shrink that bill for people paying entirely out of pocket, and home infusion services or community centers may also provide lower administration fees than hospital outpatient departments.

Some patients explore biosimilar products or seek infusions in countries where biologic list prices are lower because of national procurement, although travel costs and continuity of care need careful discussion with their specialist before any cross border care is arranged, as noted by the international resource IBD Passport and EVERSANA’s European pricing review.

Remicade vs Biosimilars

Infliximab biosimilars such as Inflectra, Avsola and Renflexis are designed to match the reference product Remicade in structure, efficacy and safety, and regulators approve them using comparability data rather than full new development programs. Reviews from the World Health Organization on switching anti-TNF biologics and gastroenterology researchers, summarized by Center for Biosimilars, report that switching from originator infliximab to a biosimilar does not change response rates, immunogenicity or discontinuation in inflammatory bowel disease or rheumatologic conditions.

In United States data, payer analyses and manufacturer reports suggest that biosimilar infliximab products are priced around 15 to 40 percent lower than the original Remicade at the level of average sales price, and one 2024 market report from Samsung Bioepis placed the average sales price for all infliximab products near $236 per 100 milligrams, with originator Remicade still slightly higher than biosimilar competitors, a pattern echoed in pricing trend summaries from the Center for Biosimilars.

Patients may not see that full discount on their bill because infusion centers can apply their own markups, but many insurers prefer Inflectra or Avsola in order to keep overall drug spending down. For United States patients, the practical question is often whether a biosimilar is on a lower formulary tier and whether switching to it would make it easier to move infusions to a lower cost site of care without changing the dosing schedule.

When a physician proposes a switch, the discussion usually focuses on disease control, insurance formulary rules and the potential copay reduction, not on changing the infusion schedule. Multiple cohort studies from European inflammatory bowel disease centers, including analyses published in the Journal of Crohn’s and Colitis, show that even after repeated switches between biosimilars, most patients stay in remission and drug survival is similar, and this evidence is one reason why national guidelines describe a move from Remicade to a biosimilar as an acceptable strategy for many stable patients.

Cost by Infusion Location

Where an infusion happens can be as important as which drug is hanging on the pole. SingleCare notes that hospital outpatient departments often bill two or three times more than physician owned infusion suites for the same infliximab dose, and My Local Infusion explains that independent centers can control overhead and keep per visit charges in the middle of the $4,000–$7,000 band for uninsured patients instead of approaching $12,000+.

The comparison in the table below illustrates typical self pay ranges before discounts in the United States based on clinic schedules and hospital transparency reports, including those from Drugs.com and Woodholme Gastroenterology.

Outside the United States, national health systems and negotiated tenders compress these gaps. A Dutch program of home based Remicade, summarized by J&J Medical Connect, found that administration excluding the drug cost averaged €229 per infusion at home compared with €284 in an infusion clinic, and the EVERSANA pricing review reported Remicade manufacturer prices around €430–€500 per 100 milligram vial across France, Germany, Italy, Spain and the United Kingdom, which translates into far lower direct patient payments than those seen in many United States self pay examples as of late 2024.

Real-World Cost Examples

Price ranges can feel abstract until they are mapped onto a real infusion calendar. The following scenarios are based on published fee schedules, benefit designs and assistance rules and are meant to show how people in different situations may see very different figures even when they receive the same drug and dose, drawing on sources such as SingleCare’s cost breakdown and Woodholme Gastroenterology’s self pay pricing.

Consider a 70 kilogram adult in Denver with moderately active Crohn’s disease who receives Remicade at an independent infusion center that bills $1,100 per 100 milligram vial and $500 for the infusion service. A 5 milligram per kilogram dose uses four vials, so medication charges reach $4,400. The facility then adds the $500 administration fee, $180 for basic lab work and $220 for a brief physician visit on the same date of service.

The allowed amount for that visit totals $5,300. If the person has a commercial plan with a remaining deductible of $1,500 and 20 percent coinsurance, their share for that visit would be the $1,500 deductible plus 20 percent of the remaining $3,800, or $760, which yields an out of pocket payment of $2,260. These details show how plan design and timing can change the final bill.

In a second scenario, a 68 year old retiree in Connecticut receives hospital outpatient infusions under Medicare Part B together with a Medicare Supplement plan that covers the Part B coinsurance. The hospital bills near the upper end of the national range, but the combination of Medicare payment rules and the Medigap policy leaves the patient paying $0 on the day of service for the drug and infusion, although they still pay monthly premiums for the supplement and Part D plan through the year. A third scenario comes from self pay care in Baltimore, where a clinic that lists $800 per vial and $400 per infusion for Remicade or Avsola works with a charitable foundation grant of about $7,500 per year from organizations such as the PAN Foundation, which can offset several infusions and drop a typical patient bill from almost $4,000 per visit to just a few hundred dollars once the grant and prompt pay discounts apply. Taken together, these examples show how Remicade infusion cost depends on the interaction between dose, insurance design, infusion setting and any assistance layered on top.

Financial Assistance Programs

Janssen, the manufacturer of Remicade, operates support programs under the J&J withMe and Janssen CarePath brands that focus on insurance verification, affordability and treatment support. The Remicade cost support page explains that eligible people with commercial insurance can use a savings card that drops the medication share to as little as $5 per infusion up to a yearly maximum, and the same service helps identify state pharmaceutical assistance programs, Medicare resources and independent copay foundations for people on public insurance or with no coverage at all, as described on the official Remicade cost support page and the J&J withMe infliximab affordability site.

Nonprofit groups such as the PAN Foundation’s rheumatoid arthritis fund, the CreakyJoints financial assistance guides and other disease specific charities periodically open funds for inflammatory bowel disease and rheumatoid arthritis biologics, offering annual grants that can pay thousands of dollars toward coinsurance or deductibles when income falls below set thresholds. These programs are subject to funding cycles and disease categories, so clinics often keep wait lists or connect patients quickly when a Remicade or infliximab category opens, and the Janssen support teams frequently provide contact details for active foundations.

Most assistance programs require proof of income, insurance details and recent explanation of benefits, and many ask for diagnosis codes or a signed form from the prescribing specialist. Arthritis and inflammatory bowel disease advocacy sites such as MyRATeam and CreakyJoints recommend keeping these documents in a single folder and asking clinic financial counselors to help submit applications so that approvals line up with upcoming infusion dates and expected outlays.

Tips to Reduce Your Infusion Cost

One practical strategy is to review every location where Remicade or its biosimilars can be given and to ask whether a community infusion center or home service is an option instead of a hospital outpatient department. Studies of biologic infusions and flat price comparisons, including those discussed by SingleCare, My Local Infusion and Healthline’s Remicade cost overview, show that moving from a hospital unit to a free standing infusion clinic can cut the allowed amount for the same dose by roughly 30 to 50 percent, which can mean thousands of dollars in yearly savings when coinsurance is applied.

Another strategy is to work with the prescriber and pharmacist to see whether a biosimilar such as Inflectra, Avsola or Renflexis is on the preferred tier of the insurance plan and whether copay assistance is available, taking into account pricing trends summarized by the Center for Biosimilars and similar sources. Coordinating infusion dates so that high cost visits fall after the deductible has been met rather than at the start of a new plan year can also lower the effective rate per session, especially for families that already carry other chronic medications or imaging expenses, a tactic that fits with guidance on deductibles from HealthCare.gov.

Hidden costs deserve attention as well, since they often appear on separate statements and can surprise people months after the infusion. Routine safety labs before a Remicade dose can run $100–$250, premedications and IV supplies another $25–$100, and extended observation or an emergency room visit for a rare infusion reaction can add $500–$2,000 or more to the annual spend, so asking the clinic to outline these charges ahead of time can help patients compare full episode costs and not just the medication line, as highlighted by United Digestive’s infusion FAQ and Medical News Today’s discussion of Remicade. Always ask for itemized bills so you can see and question each component of the charge.

Answers to Common Questions

How much does one infusion of Remicade cost?

Most sources place uninsured Remicade infusion charges around $4,000–$7,000 in United States outpatient clinics, with hospital outpatient departments sometimes billing $8,000–$12,000+ per visit before discounts or assistance, and individual bills depend on dose, location and any added services.

What factors have the biggest impact on Remicade pricing?

The largest drivers are body weight, which sets vial count, the frequency of infusions over the year, the site of care and the details of the insurance plan or lack of coverage. Administration fees, lab work, physician visits and any emergency care for infusion reactions add further variation on top of the core medication charge, as reflected in pricing tools like Drugs.com and dosing guidance on Remicade HCP pages.

Is Remicade covered by Medicare and private insurance?

Yes, Remicade is often covered under Medicare Part B and by many commercial medical plans when clinical criteria are met, though prior authorization is common and some insurers prefer biosimilars first. Patients typically face coinsurance of about 20 percent after deductibles unless they have supplemental coverage that lowers that share, according to CMS Part B drug payment files and SingleCare’s Medicare cost guides.

Are Remicade biosimilars like Inflectra usually cheaper?

Biosimilars such as Inflectra, Avsola and Renflexis are typically priced below Remicade at the average sales price level, with some reports showing 15 to 40 percent lower acquisition costs, although patient bills still depend on facility markups and insurance benefit design. Many insurers favor biosimilars on formularies in order to reduce total spending on infliximab therapy, as summarized in Samsung Bioepis market reports and Center for Biosimilars pricing trend articles.

Where can I find financial help for Remicade infusions?

People on commercial insurance can look at manufacturer savings programs such as J&J withMe for Remicade, while those on Medicare or with no coverage often work with nonprofit groups such as the PAN Foundation, HealthWell Foundation and other disease specific charities that offer grants for biologic drugs when funds are open. Clinic financial counselors and patient advocacy sites maintain current lists of assistance resources.